Stefano Fortuzzi

Stefano Fortuzzi

Auto-generated profile, based on publicly available information

Stefano Fortuzzi

Cogentech, Consortium for Genomic Technologies

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
N(Netherlands Collaborative Group on Hereditary Breast and Ovarian Cancer (HEBON)
Netherlands Collaborative Group on Hereditary Breast and Ovarian Cancer (HEBON)
MGMaya Ghoussaini
Maya Ghoussaini
F(Familial Breast Cancer Study (FBCS)
Familial Breast Cancer Study (FBCS)
TNThe Gene Environment Interaction Of Breast Cancer In Germany (Genica) Network
The Gene Environment Interaction Of Breast Cancer In Germany (Genica) Network
KIkConFab Investigators
kConFab Investigators
DEDouglas F Easton
Douglas F Easton
Douglas Easton and colleagues report a genome-wide association analyses for breast cancer in ~70,000 cases and ~68,000 controls. They identify three new breast cancer susceptibility loci, two of which show association only with estrogen receptor–positive disease. Breast cancer is the most common cancer among women. To date, 22 common breast cancer susceptibility loci have been identified accounting for ∼8% of the heritability of the disease. We attempted to replicate 72 promising associations from two independent genome-wide association studies (GWAS) in ∼70,000 cases and ∼68,000 controls from 41 case-control studies and 9 breast cancer GWAS. We identified three new breast cancer risk loci at 12p11 (rs10771399; P = 2.7 × 10−35), 12q24 (rs1292011; P = 4.3 × 10−19) and 21q21 (rs2823093; P = 1.1 × 10−12). rs10771399 was associated with similar relative risks for both estrogen receptor (ER)-negative and ER-positive breast cancer, whereas the other two loci were associated only with ER-positive disease. Two of the loci lie in regions that contain strong plausible candidate genes: PTHLH (12p11) has a crucial role in mammary gland development and the establishment of bone metastasis in breast cancer, and NRIP1 (21q21) encodes an ER cofactor and has a role in the regulation of breast cancer cell growth.

3 February 2014 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MVMarco Vitellaro
Marco Vitellaro
PSP. Sala
P. Sala
SSStefano Signoroni
Stefano Signoroni
PRPaolo Radice
Paolo Radice
SFS. Fortuzzi
S. Fortuzzi
Lucio BertarioLucio Bertario
Lucio Bertario

24 December 2010 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
PPPaolo Peterlongo
Paolo Peterlongo
ICIrene Catucci
Irene Catucci
GPGraziella Pasquini
Graziella Pasquini
PVPaolo Verderio
Paolo Verderio
BPBernard Peissel
Bernard Peissel
PRPaolo Radice
Paolo Radice

15 May 2012 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
AJAnna Jakubowska
Anna Jakubowska
DRD Rozkrut
D Rozkrut
AAA Antoniou
A Antoniou
UHU Hamann
U Hamann
RSR J Scott
R J Scott
CCCIMBA, the Consortium of Investigators of Modifiers of BRCA1/2-Related Cancer
CIMBA, the Consortium of Investigators of Modifiers of BRCA1/2-Related Cancer
Background: The variable penetrance of breast cancer in BRCA1/2 mutation carriers suggests that other genetic or environmental factors modify breast cancer risk. Two genes of special interest are prohibitin (PHB) and methylene-tetrahydrofolate reductase (MTHFR), both of which are important either directly or indirectly in maintaining genomic integrity. Methods: To evaluate the potential role of genetic variants within PHB and MTHFR in breast and ovarian cancer risk, 4102 BRCA1 and 2093 BRCA2 mutation carriers, and 6211 BRCA1 and 2902 BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) were genotyped for the PHB 1630 C>T (rs6917) polymorphism and the MTHFR 677 C>T (rs1801133) polymorphism, respectively. Results: There was no evidence of association between the PHB 1630 C>T and MTHFR 677 C>T polymorphisms with either disease for BRCA1 or BRCA2 mutation carriers when breast and ovarian cancer associations were evaluated separately. Analysis that evaluated associations for breast and ovarian cancer simultaneously showed some evidence that BRCA1 mutation carriers who had the rare homozygote genotype (TT) of the PHB 1630 C>T polymorphism were at increased risk of both breast and ovarian cancer (HR 1.50, 95%CI 1.10–2.04 and HR 2.16, 95%CI 1.24–3.76, respectively). However, there was no evidence of association under a multiplicative model for the effect of each minor allele. Conclusion: The PHB 1630TT genotype may modify breast and ovarian cancer risks in BRCA1 mutation carriers. This association need to be evaluated in larger series of BRCA1 mutation carriers.

1 September 2014 in Genetics in Medicine
Verified
Journal Article
Closed access
ICIrene Catucci
Irene Catucci
PPPaolo Peterlongo
Paolo Peterlongo
SCSara Ciceri
Sara Ciceri
MCMAra Colombo
MAra Colombo
GPGraziella Pasquini
Graziella Pasquini
PRPaolo Radice
Paolo Radice

1 January 2015 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
PPPaolo Peterlongo
Paolo Peterlongo
JCJenny Chang-Claude
Jenny Chang-Claude
KMKirsten B. Moysich
Kirsten B. Moysich
ARAnja Rudolph
Anja Rudolph
RSRita K. Schmutzler
Rita K. Schmutzler
OIon behalf of KConFab Investigators
on behalf of KConFab Investigators
Background: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests the existence of genetic and nongenetic modifying factors. In this study, we evaluated the putative role of variants in many candidate modifier genes. Methods: Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known variants (n = 3,248) located within or around 445 candidate genes, were available through the iCOGS custom-designed array. Breast and ovarian cancer association analysis was performed within a retrospective cohort approach. Results: The observed P values of association ranged between 0.005 and 1.000. None of the variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 mutation carriers, after multiple testing adjustments. Conclusion: There is little evidence that any of the evaluated candidate variants act as modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers. Impact: Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies. Cancer Epidemiol Biomarkers Prev; 24(1); 308–16. ©2014 AACR.